La catena delle opzioni mostra i dati chiave delle opzioni azionarie di GOLD HART COPPER CORP by GOLD HART COPPER CORP. a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per GOLD HART COPPER CORP by GOLD HART COPPER CORP...

GOLD HART COPPER CORP by GOLD HART COPPER CORP. (OTC:GHCCF) Azioni, Catena delle Opzioni

GOLD HART COPPER CORP by GOLD HART COPPER CORP.

News

BLCO

Bausch + Lomb Uses Survey Insights And Patient Input To Clarify Dry Eye Realities

Adagene Inc. ("Adagene or the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise by Sanofi (Euronext: SAN FP).
Sanofi has agreed to make strategic investment of up to US$25 million in Adagene. The Company plans to use the proceeds to fund its research and development activities, including clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer (MSS CRC).
To further explore the clinical potential of muzastotug, Adagene will supply Sanofi with muzastotug to evaluate the safety, efficacy, pharmacokinetics and biomarker data in combination with other anticancer therapies in over 100 patients in a phase 1/2 clinical trial in advanced solid tumors. Adagene continues to own worldwide commercial rights to muzastotug.
Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene's proprietary masking technology and antibody engineering expertise. The bispecific therapeutic, with undisclosed targets, will be engineered by Adagene and induces an option exercise fee, as well as milestones and royalties as per the 2022 partnership agreement with Adagene.

ADAG

Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials

NVCR

Novocure To Present Final PANOVA-3 Secondary Data At ESMO GI 2025; TTFields Shows Pain Relief, QoL Gains In Pancreatic Cancer

<ul>
<li>Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI.</li>
<li>Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN</li>
<li>Non-dilutive financing further strengthens Apellis' balance sheet</li>
<li>Apellis retains full U.S. commercialization rights for systemic pegcetacoplan</li>
<li>Transaction underscores shared confidence in the meaningful growth potential in rare kidney diseases</li>
</ul>

Biotech

Health Care

Contracts

General

APLS

Apellis Pharmaceuticals Announced A Capped Royalty Purchase Agreement With Sobi Under Which Apellis Will Receive Up To $300M In Exchange For 90% Of Apellis' Future Ex-U.S. Royalties For Aspaveli (Systemic Pegcetacoplan)

QBTS

D-Wave Completes $400M ATM Equity Offering; Explores Strategic Acquisitions To Expand Quantum Leadership

ZCAR

Zoomcar Partners With CARS24 To Bring Vehicle Inspection And Tracking Standards To Self-Drive Car-Sharing Space

Nokia today announced its latest venture, Enscryb, an energy innovation platform, is partnering with NODES, an energy trading company. In addition, Enscryb has also secured and onboarded two customers: Nanuq, a charging infrastructure company, and Smartecon, a renewable energy provider.

Nokia Announced Enscryb Partnership With NODES For Energy Innovation Platform; Onboards Nanuq And Smartecon As Initial Customers

TLRY

Tilray-Owned Breckenridge Distillery Debuts New Collectors Art Series Bottle Featuring Calvados Cask Finish And Toland Mural

<ul>
<li>Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.</li>
<li>Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH&#xAE; (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025.</li>
<li>Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget.</li>
<li>Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for this multi-billion dollar addressable market.</li>
<li>Company expects to dose first patient in the Phase 3 trial in the United States in the fourth quarter of 2025.</li>
<li>Verrica to maintain ownership of global rights to YCANTH for all indications in all territories outside of Japan</li>
</ul>

VRCA

Verrica Pharmaceuticals Announces Second Amendment To Its Existing Collaboration And Licensing Agreement With Torii Pharmaceutical To Initiate A Global Pivotal Phase 3 Trial Of Verrica's Ycanth For Common Warts

Establishes Digital Computing Division to Drive Company's Digital Infrastructure Strategy, Adds Hash Rate of 3.11 EH/s, Expects Significant Bitcoin Mining Revenue, Sets Stage for Future High-Performance Computing (HPC) and AI-driven Entertainment Services Opportunities
ABU DHABI, United Arab Emirates, July 01, 2025 (GLOBE NEWSWIRE) -- NIP Group Inc. ("NIPG" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>), a leading digital entertainment company, today announced it has entered into a definitive asset-purchase agreement (the "Agreement") to acquire on-rack crypto mining machines (the "Products") from Fortune Peak Limited and Apex Cyber Capital Limited (together, the "Sellers"). These Products are currently used for Bitcoin mining and are expected to begin generating significant Bitcoin mining revenue for the Company upon closing of the acquisition. To support this initiative, NIPG has established a dedicated Digital Computing Division to manage the operations of the acquired Products and lead the future development of the Company's compute infrastructure capabilities. Importantly, this transaction marks a strategic extension of NIPG's business into the digital infrastructure space.
The Products, consisting of data center capacity with a combined hash rate of 3.11 EH/s, are currently utilized for Bitcoin mining operations with expected production of approximately 60 Bitcoins per month, and will continue operating immediately after closing of the proposed transaction. Under the terms of the Agreement, NIPG will pay the consideration for the Products through issuance of approximately 119,553,439 Class A ordinary shares of the Company to the Sellers. In connection with the consummation of the proposed transactions contemplated by the Agreement, the Company and the Sellers will also enter into an investor rights agreement to define certain rights and obligations among them with respect to the Company.
The closing of the proposed transaction is expected to occur on or before September 30, 2025, and is subject to customary closing conditions. There can be no assurance that the closing conditions will be satisfied nor that the proposed transaction will be completed before that date or at all.

NIPG

NIP Group Enters Into Definitive Asset-Purchase Agreement To Acquire On-Rack Crypto Mining Machines From Fortune Peak Limited And Apex Cyber Capital Limited

NIVF

NewGen Subsidiary Secures UAE Beachfront Plot; Explores Real World Asset Tokenization Amid $45M Real Estate Push

EDAP TMS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TMS S.A. (the "Company") currently qualifies as a foreign private issuer under applicable U.S. Securities and Exchange Commission ("SEC") rules and regulations. Effective January 1, 2026, the Company will no longer qualify for foreign private issuer status and will begin complying with and reporting under SEC reporting and other rules and Nasdaq listing requirements applicable to U.S. domestic filers, including, but not limited to, requirements with respect to the composition of the Company's board of directors and committees, certain corporate governance matters and shareholder approval of certain actions.

Government

Regulations

EDAP

EDAP TMS Will No Longer Qualify as Foreign Issuer, Adopts US Reporting Rules

Digital Realty Reaches 1.5 GW Of Renewable Energy Capacity Under Contract And Matching 185 Data Centers With 100% Renewable Energy

Management

JBIO

Jade Biosciences Appoints Brad Dahms As Chief Financial Officer

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs,&nbsp;today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy.
Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and industry and has contributed to the successful filing of more than 25 Investigational New Drug (IND) applications. He joins Avacta from Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies. Prior to that, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science. At Vaxart, Dr. Liebowitz led the acquisition and execution of a significant BARDA contract as principal investigator, culminating in successful completion of the award. Earlier in his career, he held key R&amp;D leadership roles at Amgen, where he directed oncology and vascular biology drug discovery at the company's Washington research site.
 &nbsp;

Avacta Appoints Dr. David Liebowitz as Chief Medical Officer to Lead Cancer Drug Strategy

INVX

Innovex Completes All-Cash Divestment Of Subsea Tree Product Line To Trendsetter Engineering

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $44 price target.

Price Target

Reiteration

Analyst Ratings

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

BTAI

BioXcel Therapeutics Announced The Second Positive Recommendation By An Independent Data Safety Monitoring Board To Continue, Without Modification, SERENITY At-home Pivotal Phase 3 Safety Trial Of BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia

<a href="https://www.globenewswire.com/Tracker?data=B7tw_SO0EIaKsJ8U2ptgerj7MQYCVzKu9NFy1vl5dbf25_WFwPTEk9FUz6pFUgrxvl9l8LMTwVdxsDfKbDsPBxe-e-QJ8GEz1U8K3jJGCbs=">Banzai International, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) ("Banzai" or the "Company"), a leading marketing technology company that provides essential marketing and sales solutions, today announced the completion of an $11.0 million dollar debt facility with an institutional investor to support acquisitions and ongoing operations.
The financing includes an initial tranche of $2.2 million (the "Note"), which matures on June 30, 2026, bears interest at 10% per annum, and is secured by the Company's assets. The principal amount of the Note is payable in cash or convertible in whole or in part into common shares at the holder's discretion at 115% of the price of the common stock immediately preceding the Closing Date. The company has the right to draw subsequent tranches, provided that certain conditions are met or waived.
Banzai intends to use the net proceeds from the facility for working capital, acquisitions, and general corporate purposes to support its future growth.

BNZI

Banzai Secures $11M Debt Deal to Fuel Acquisitions and Growth Plans

KIRK

Kirkland's Appoints Andrea Courtois As SVP, CFO, Succeeding Mike Madden, Effective July 21, 2025

Comments

GOLD HART COPPER CORP by GOLD HART COPPER CORP.

GOLD HART COPPER CORP by GOLD HART COPPER CORP. (GHCCF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO